NDAORALTABLET
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
16
Data completeness
4/8 — Partial
Drug data last refreshed 4m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XPHOZAH (tenapanor) is an oral small-molecule therapeutic approved by the FDA in October 2023. The drug is indicated for hyperphosphatemia management in patients with chronic kidney disease on dialysis, working through a novel mechanism to reduce phosphate absorption in the gastrointestinal tract. It represents Ardelyx's first major commercial launch and addresses a significant unmet need in nephrology.
$0.001BPart D
GrowthGrowing
16.4 years to LOEEarly-stage growth product with significant room for market expansion; commercial team is likely building infrastructure for broader adoption across dialysis centers.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
Started Jan 2026
692 enrolled
Chronic Idiopathic Constipation (CIC)
Assessing Tenapanor as a Treatment of CF-related Constipation.
Started Jun 2025
25 enrolled
Cystic FibrosisConstipation
Tenapanor in Synucleinopathy-Related Constipation
Started Jan 2025
30 enrolled
SynucleinopathyParkinson's Disease
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
Started Jul 2024
72 enrolled
Irritable Bowel Syndrome With Constipation (IBS-C)
Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation
Started Feb 2024
36 enrolled
IBSIBS - Irritable Bowel Syndrome
Worked on XPHOZAH at Ardelyx? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.